Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Free Cash Flow (2016 - 2025)

Dexcom (DXCM) has disclosed Free Cash Flow for 16 consecutive years, with $192.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 8.65% to $192.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 70.79% year-over-year, with the annual reading at $1.1 billion for FY2025, 70.79% up from the prior year.
  • Free Cash Flow for Q4 2025 was $192.1 million at Dexcom, down from $579.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $579.4 million in Q3 2025, with the low at -$71.9 million in Q1 2021.
  • Average Free Cash Flow over 5 years is $128.9 million, with a median of $114.0 million recorded in 2025.
  • The sharpest move saw Free Cash Flow plummeted 141.29% in 2021, then surged 556.17% in 2025.
  • Over 5 years, Free Cash Flow stood at $25.6 million in 2021, then soared by 169.53% to $69.0 million in 2022, then grew by 17.54% to $81.1 million in 2023, then surged by 118.0% to $176.8 million in 2024, then increased by 8.65% to $192.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $192.1 million, $579.4 million, and $208.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.